Omeros’ narsoplimab headed for 1H20 submission on back of readout

Omeros is planning a follow-on offering and completion of a rolling BLA for narsoplimab after releasing the first set of pivotal data for the mAb to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy, an Orphan indication with no

Read the full 389 word article

User Sign In